Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.24)
# 2,661
Out of 5,182 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $22.09 | -9.46% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $27.75 | -45.95% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $16.27 | -50.83% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $24.61 | +103.17% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $130.90 | +3.90% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $5.54 | +188.81% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $10.36 | +498.46% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $2.47 | +385.83% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $23.08 | +372.27% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $2.63 | +204.18% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.79 | +163.85% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $8.22 | +1,117.29% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $41.79 | -85.64% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.14 | +194.12% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $163.03 | -85.89% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $62.13 | -42.06% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $22.09
Upside: -9.46%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $27.75
Upside: -45.95%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $16.27
Upside: -50.83%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $24.61
Upside: +103.17%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $130.90
Upside: +3.90%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $5.54
Upside: +188.81%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $10.36
Upside: +498.46%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $2.47
Upside: +385.83%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $23.08
Upside: +372.27%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $2.63
Upside: +204.18%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.79
Upside: +163.85%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $8.22
Upside: +1,117.29%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $41.79
Upside: -85.64%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $7.14
Upside: +194.12%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $163.03
Upside: -85.89%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $62.13
Upside: -42.06%